Lupin receives FDA approval for generic Temovate Ointment, 0.05%
09 May 2018 | News
Clobetasol Propionate Ointment USP, 0.05% had annual sales of approximately 120 million in the US
Pharma major Lupin announced that it has received final approval for its Clobetasol Propionate Ointment USP, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%.
Lupin’s Clobetasol Propionate Ointment USP, 0.05% is the AB rated generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%. It is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Clobetasol Propionate Ointment USP, 0.05% had annual sales of approximately 120 million in the US (IQVIA MAT January 2018).
